Yungjin Pharmaceuticals

Seoul, South Korea Founded: 1952 • Age: 74 yrs Listed
Pharmaceutical products are manufactured in South Korea.

About Yungjin Pharmaceuticals

Yungjin Pharmaceuticals is a publicly listed company based in Seoul (South Korea) founded in 1952. Pharmaceutical products are manufactured in South Korea. The company has 628 employees. Its chief executive, as recorded, is Lee Chae Joon. Its website yungjin.co.kr draws about 29 thousand monthly visits. Yungjin Pharmaceuticals offers products and services including Pharmaceuticals and Health Foods. Its focus areas include Traditional Pharmaceuticals. Its legal entity is Yungjin Pharmaceutical Co., Ltd.

Company details

Yungjin Pharmaceuticals was established in 1952 and is headquartered in Seoul, South Korea. Operations are focused on the manufacturing of pharmaceutical products within the healthcare sector. The company is led by CEO Lee Chae Joon. Activities encompass production processes tailored to pharmaceutical standards, with a primary emphasis on domestic markets. Geographic presence remains centered in South Korea, supporting regional healthcare needs through established facilities.

  • Headquarters Seoul, South Korea
  • Employees 628
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    •••• ••••
  • Website yungjin.co.kr/index.asp
  • Social LinkedIn
  • Legal Name Yungjin Pharm. Co. Ltd
Key Metrics
  • Annual Revenue
    $176.06 M (USD)
    0.88
    as on Dec 31, 2025
  • Net Profit
    -$157.64 K (USD)
    -118.47
    as on Dec 31, 2025
  • EBITDA
    $8.45 M (USD)
    -30.03
    as on Dec 31, 2025
  • Employee Count
    628

Products & Services of Yungjin Pharmaceuticals

Yungjin Pharmaceuticals offers a comprehensive portfolio of products and services, including Pharmaceuticals and Health Foods.

Pharmaceuticals
Medicines

Various prescription and over-the-counter medicines are developed and distributed for treating chronic and other health conditions.

Health Foods
Nutritional Products

Health foods and supplements are provided to support consumer well-being and nutritional needs.

People of Yungjin Pharmaceuticals

1 people are tracked at Yungjin Pharmaceuticals (1 in leadership); the tracked headcount is 628.

NameRoleGroup
Lee Chae Joon
CEOLeadership
Premium access

Complete people profiles for Yungjin Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Yungjin Pharmaceuticals

Yungjin Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 003520 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Jun 1973
  • Listed onKRX: 3520
  • Listed entityYUNGJIN PHARM. CO. LTD
  • Exchange sectorHealth technology
  • ISINKR7003520004
  • Share price996.00 KRW (-1.29% on the day) · 2026-10-14
  • Market capitalisation184,538,488,159.00 KRW
  • EPS (diluted, trailing year)-34.21 KRW
  • Volume (last session)264,171

Financials of Yungjin Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025254.26B KRW-227.7M KRW12.20B KRW
2024252.04B KRW1.23B KRW17.44B KRW
2023234.90B KRW-3.88B KRW11.81B KRW
2022218.38B KRW-21.96B KRW316.8M KRW
2021196.07B KRW-11.58B KRW-6.50B KRW
Premium access

Detailed financial statements for Yungjin Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Web traffic of Yungjin Pharmaceuticals

The website of Yungjin Pharmaceuticals (yungjin.co.kr) receives about 28.9K visits a month and ranks #1,158,865 among all websites worldwide, #1,450 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    28.9K

    ▲ 2.4% vs previous month

  • Unique visitors
    5.1K

    per month

  • Global rank
    #1,158,865

    among all websites

  • Category rank
    #1,450

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Yungjin Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
medical-tribune.co.kr
medical-tribune.co.kr
100%
#1,257,589–
choa.co.kr
100%
14K#1,738,079View details
medisobizanews.com
99%
#283,693View details
medipana.com
medipana.com
99%
#266,587–
hyundaipharm.co.kr
99%
25.8K#1,103,659View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Yungjin Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Yungjin Pharmaceuticals

Premium access

Complete news archive for Yungjin Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yungjin Pharmaceuticals

Yungjin Pharmaceuticals was founded in 1952.

Yungjin Pharmaceuticals is headquartered in Seoul, South Korea.

Lee Chae Joon is the CEO of Yungjin Pharmaceuticals, as recorded in our data.

Yungjin Pharmaceuticals has 628 employees.

Annual revenue of Yungjin Pharmaceuticals is $176.06M as on Dec 31, 2025.

Yungjin Pharmaceuticals was established in 1952 and is headquartered in Seoul, South Korea. Operations are focused on the manufacturing of pharmaceutical products within the healthcare sector. The company is led by CEO Lee Chae Joon. Activities encompass production processes tailored to pharmaceutical standards, with a primary emphasis on domestic markets. Geographic presence remains centered in South Korea, supporting regional healthcare needs through established facilities.

Yungjin Pharmaceuticals offers Pharmaceuticals and Health Foods.

Yes, Yungjin Pharmaceuticals is publicly traded on KRX under the ticker symbol 003520.

Yungjin Pharmaceuticals operates through Yungjin Pharmaceutical Co., Ltd.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available